Prognostic and Predictive Factors in Patients Treated with Chemotherapy for Advanced Urothelial Cancer: Where Do We Stand?

References

• Foster CS , RossJS. Pathology of the Urinary Bladder.Saunders, PA, USA, 183–267 (2004).
   Google Scholar
• Siegel R , NaishadhamD, JemalA. Cancer statistics 2012. CA Cancer J. Clin.62(1), 10–29, (2012).
   PubMed Web of Science ®Google Scholar
• Kogenivas M , MannetjeAT, CordierSet al. Occupation and bladder cancer. among men in western Europe. Cancer Causes Control14(10), 907–914 (2003).
   PubMed Web of Science ®Google Scholar
• Roth BJ , BajorinDF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J. Urol.153(3 Pt 2), 894–900 (1995).
   PubMed Web of Science ®Google Scholar
• Von der Maase H , SengelovL, RobertsJTet al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Costantini C , MillardF. Update on chemotherapy in the treatment of urothelial carcinoma. Sci. World J.11, 1981–1994 (2011).
   Google Scholar
• Albers P , ParkSI, NiegischGet al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol.22(2), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Naiki T , KawaiN, HashimotoYet al. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int. J. Clin. Oncol.19(3), 516–522 (2014).
   PubMed Web of Science ®Google Scholar
• Pond GR , BellmuntJ, FougerayRet al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin. Genitourin. Cancer11(4), 495–500 (2013).
   PubMed Web of Science ®Google Scholar
• Dogliotti L , CartenìG, SienaSet al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol.52(1), 134–141 (2007).
   PubMed Web of Science ®Google Scholar
• Buti S . Does the cetuximab plus paclitaxel combination deserve to be studied in a Phase III trial?J. Clin. Oncol.31(12), 1613–1614 (2013).
   PubMed Web of Science ®Google Scholar
• NIH . ClinicalTrials.gov.https://clinicaltrials.gov
   Google Scholar
• Logothetis CJ , DexeusFH, FinnLet al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol.8(6), 1050–1055 (1990).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr , EinhornLH, ElsonPJet al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Saxman SB , PropertKJ, EinhornLHet al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.15(7), 2564–2569 (1997).
   PubMed Web of Science ®Google Scholar
• Sengel⊘v L , KambyC, SchouG, von der MaaseH. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer74(1), 123–133 (1994).
   PubMed Web of Science ®Google Scholar
• Sengel⊘v L , NielsenOS, KambyC, von der MaaseH. Platinum analogue combination chemotherapy: cisplatin, carboplatin and methotrexate in patients with metastatic urothelial tract tumors. A Phase II trial with evaluation of prognostic factors. Cancer76(10), 1797–1803 (1995).
   PubMed Web of Science ®Google Scholar
• Bajorin DF , DoddPM, MazumdarMet al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol.17(10), 3173–3181 (1999).
   PubMed Web of Science ®Google Scholar
• Sengel⊘v L , KambyC, GeertesenP, AndersenLJ, von der MaaseH. Predictive factors of response to cispltin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol.46(5), 357–364 (2000).
   PubMed Web of Science ®Google Scholar
• Sengel⊘v L , KambyC, von der MaaseH. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur. Urol.39(6), 634–642 (2001).
   PubMed Web of Science ®Google Scholar
• Stadler WM , AnnamariaH, von der MaaseHet al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol. Oncol.7(4), 153–157 (2002).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , AlbanellJ, Paz-AresLet al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer95(4), 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Roychowdhury DF , HaydenA, LiepaAM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J. Clin. Oncol.21(4), 673–678 (2003).
   PubMed Web of Science ®Google Scholar
• Bamias A , AravantinosG, DeliveliotisCet al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol.22(2), 220–228 (2004).
   PubMed Web of Science ®Google Scholar
• Bamias A , EfstathiouE, MoulopoulosLAet al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann. Oncol.16(2), 307–313 (2005).
   PubMed Web of Science ®Google Scholar
• Lin CC , HsuCH, HuangCYet al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology69(3), 479–484 (2007).
   PubMed Web of Science ®Google Scholar
• Jessen C , AgerbaekM, Von Der MaaseH. Predictive factors for response and prognostic factors for long-term urvival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol.48(3), 411–417 (2009).
   PubMed Web of Science ®Google Scholar
• Matsumura N , NakamuraY, KohjimotoYet al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer. treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int.108 (2 Pt 2), E110–E116 (2010).
   PubMedGoogle Scholar
• De Santis M , BellmuntJ, MeadGet al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol.30(2), 191–199 (2012).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , von der MaaseH, MeadGMet al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol.30(10), 1107–1111 (2012).
   PubMed Web of Science ®Google Scholar
• Nakagawa T , HaraT, KawaharaTet al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J. Urol.189(4), 1275–1281 (2013).
   PubMed Web of Science ®Google Scholar
• Taguchi S , NakagawaT, HattoriMet al. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J. Clin. Oncol.43(9), 923–928 (2013).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , ChoueiriTK, FougerayRet al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol.28(11), 1850–1855 (2010).
   PubMed Web of Science ®Google Scholar
• Niegisch G , FimmersR, SienerRet al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur. Urol.60(5), 1087–1096 (2011).
   PubMed Web of Science ®Google Scholar
• Ikeda M , MatsumotoK, TabataKet al. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J. Clin. Oncol.41(10), 1214–1220 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JL , AhnJH, ParkSHet al. Phase II study of a Cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest. New Drugs30(5), 1984–1990 (2012).
   PubMed Web of Science ®Google Scholar
• Krajewski KM , FougerayR, BellmuntJet al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur. J. Cancer48(10), 1495–1502 (2012).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , RossRW, JacobusSet al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol.30(5), 507–512 (2012).
   PubMed Web of Science ®Google Scholar
• Ko YJ , CanilCM, MukherjeeSDet al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, Phase 2 study. Lancet Oncol.14(8), 769–776 (2013).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , ThéodoreC, DemkovTet al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ , SrinivasS, StadlerWMet al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial cancer: results of a large Phase II study. Cancer115(18), 4110–4117 (2009).
   PubMed Web of Science ®Google Scholar
• Olaussen KA , DunantA, FouretPet al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355(10), 983–991 (2006).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , Paz-AresL, CuelloMet al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer. patients receiving cisplatin-based chemotherapy. Ann. Oncol.18(3), 522–528 (2007).
   PubMed Web of Science ®Google Scholar
• Hoffmann AC , WildP, LeichtCet al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer. receiving adjuvant chemotherapy. Neoplasia12(8), 628–636 (2010).
   PubMed Web of Science ®Google Scholar
• Kawashima A , TakayamaH, KawamuraNet al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol. Lett.4(1), 15–21 (2012).
   PubMed Web of Science ®Google Scholar
• Krüger S , WeitschG, BüttnerHet al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int. J. Oncol.21(5), 981–987 (2002).
   PubMed Web of Science ®Google Scholar
• Miyamoto H , KubotaY, NoguchiSet al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology55(5), 679–683. (2000)
   PubMed Web of Science ®Google Scholar
• van Oers JM , ZwarthoffEC, RehmanIet al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol.55(3), 650–657 (2009).
   PubMed Web of Science ®Google Scholar
• Tomlinson DC , LamontFR, ShnyderSDet al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res.69(11), 4613–4620. (2009).
   PubMed Web of Science ®Google Scholar
• Tomlinson DC , KnowlesMA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol.77(5), 2379–2386. (2010).
   Google Scholar
• Kopparapu PK , BoorjianSA, RobinsonBDet al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res.33(6), 2381–2390 (2013).
   PubMed Web of Science ®Google Scholar
• Inoue K , SlatonJW, KimSJet al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res.60(8), 2290–2299 (2000).
   PubMed Web of Science ®Google Scholar
• Garg M , KanojiaD, SethAet al. Heat-shock protein 70–2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur. J. Cancer46(1), 207–215. (2010).
   PubMed Web of Science ®Google Scholar
• Kamada M , SoA, MuramakiMet al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer. cells. Mol. Cancer Ther.6(1), 299–308. (2007).
   PubMed Web of Science ®Google Scholar
• Hansel DE , PlattE, OrloffMet al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am. J. Pathol.176(6), 3062–3072 (2010).
   PubMed Web of Science ®Google Scholar
• Iyer G , HanrahanAJ, MilowskyMIet al. Genome sequencing identifies a basis for everolimus sensitivity. Science338(6104), 221 (2012).
   PubMed Web of Science ®Google Scholar
• Zaharieva B , SimonR, RuizCet al. High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int. J. Cancer117(6), 952–956. (2005).
   PubMed Web of Science ®Google Scholar
• Choi JW , KimY, LeeJH, KimYS. Expression of β-tubulin isotypes in urothelial carcinoma of the bladder. World J. Urol.32(2), 347–352 (2014).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ , MilowskyMI, IshillNet al. Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol.20(2), 305–308. (2009).
   PubMed Web of Science ®Google Scholar
• Ioachim E , MichaelMC, SalmasMet al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer6, 140 (2006).
   PubMed Web of Science ®Google Scholar
• Furuta T , UedaT, AuneGet al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res.62(17), 4899–4902 (2002).
   PubMed Web of Science ®Google Scholar
• Park CH , BesshoT, MatsunagaT, SancarA. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem.270(39), 22657–22660 (1995).
   PubMed Web of Science ®Google Scholar
• Mu D , HsuDS, SancarA. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem.271(14), 8285–8294 (1996).
   PubMed Web of Science ®Google Scholar
• Matsunaga T , MuD, ParkCH, ReardonJT, SancarA. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J. Biol. Chem.270(35), 20862–20869 (1995).
   PubMed Web of Science ®Google Scholar
• Shirota Y , StoehlmacherJ, BrabenderJet al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol.19(23), 4298–4304 (2001).
   PubMed Web of Science ®Google Scholar
• Metzger R , LeichmanCG, DanenbergKDet al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol.16(1), 309–316 (1998).
   PubMed Web of Science ®Google Scholar
• Dabholkar M , VionnetJ, Bostick-BrutonF, YuJJ, ReedE. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum based chemotherapy. J. Clin. Invest.94(2), 703–708 (1994).
   PubMed Web of Science ®Google Scholar
• Joshi MB , ShirotaY, DanenbergKDet al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res.11(6), 2215–2221 (2005).
   PubMed Web of Science ®Google Scholar
• Sun JM , AhnMJ, ParkMJet al. Expression of excision repair cross-complementation group 1 as a predictive marker for nasopharyngeal cancer trated with concurrent chemoradiotherapy. Int. J. Oncol. Biol. Phys.80(3), 655–660 (2011).
   PubMed Web of Science ®Google Scholar
• Usanova S , Piée-StaffaA, SiedUet al. Cisplatin sensitivity of testis tumour cells due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer9, 248 (2010).
   PubMed Web of Science ®Google Scholar
• Kawashima A , TakayamaH, TsujimuraA. A review of ERCC1 gene in bladder cancer: implications for carcinogenesis and resistance to chemoradiotherapy. Adv. Urol.2012, 812398 (2012).
   PubMedGoogle Scholar
• Kawashima A , NakayamaM, KakutaYet al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin. Cancer Res.17(8), 2561–2569 (2011).
   PubMed Web of Science ®Google Scholar
• Brabletz TA , JungA, ReuSet al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor microenvironment. Proc. Natl Acad. Sci. USA98(18), 10356–10361 (2001).
   PubMed Web of Science ®Google Scholar
• Nakajima S , DoiR, ToyodaEet al. N-cadherin expression and epithelial–mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res.10(12 Pt 1), 4125–4133 (2004).
   PubMed Web of Science ®Google Scholar
• McConkey DJ , ChoiW, MarquisLet al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev.28(3–4), 335–344 (2009).
   PubMed Web of Science ®Google Scholar
• Rieger-Christ KM , NgL, HanleyRSet al. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br. J. Cancer92(12), 2153–2159 (2005).
   PubMed Web of Science ®Google Scholar
• Gee J , GreatheadP, LittleAFet al. Aberrant cadherin expression in bladder carcinoma cells. Mol. Urol.2(2), 73–81 (1998).
   Google Scholar
• Hsu DSS , LanHY, HuangCHet al. Regulation of excision repair cross-complementation group 1 by snail contribuites to cisplatin resistance in head and neck cancer. Clin. Cancer Res.16(18), 4561–4571 (2010).
   PubMed Web of Science ®Google Scholar
• Mackey JR , ManiRS, SelnerMet al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res.58(19), 4349–4357 (1998).
   PubMed Web of Science ®Google Scholar
• Achiwa H , OguriT, SatoS, MaedaH, NiimiT, UedaR. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci.95(9), 753–757 (2004).
   PubMed Web of Science ®Google Scholar
• Spratlin J , SanghaR, GlubrechtDet al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res.10(20), 6956–6961 (2004).
   PubMed Web of Science ®Google Scholar
• Farré X , Guillén-GómezE, SánchezLet al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer112(6), 959–966 (2004).
   PubMed Web of Science ®Google Scholar
• Mey V , GiovannettiE, De BraudFet al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer. patients. Br. J. Cancer95(3), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Sève P , DumontetC. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?Lancet Oncol.9(2), 168–175 (2008).
   PubMed Web of Science ®Google Scholar
• Esrig D , SpruckCH3rd, NicholsPWet al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol.143(5), 1389–1397 (1993).
   PubMed Web of Science ®Google Scholar
• Esrig D , ElmajianD, GroshenSet al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med.331(19), 1259–1264 (1994).
   PubMed Web of Science ®Google Scholar
• Sarkis AS , DalbagniG, Cordon-CardoCet al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst.85(1), 53–59 (1993).
   PubMedGoogle Scholar
• Lipponen PK . Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer. and its prognostic value. Int. J. Cancer53(3), 365–370 (1993).
   PubMed Web of Science ®Google Scholar
• Stadler WM , LernerSP, GroshenSet al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol.29(25), 3443–3449 (2011).
   PubMed Web of Science ®Google Scholar
• Sarkis AS , BajorinDF, ReuterVEet al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol.13(6), 1384–1390 (1995).
   PubMed Web of Science ®Google Scholar
• Yancik R , RiesLA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol. Oncol. Clin. North Am.14(1), 17–21 (2000).
   PubMed Web of Science ®Google Scholar
• Balducci L , ExtermannM. Management of cancer in the older person: a practical approach. Oncologist5(3), 224–237 (2000).
   PubMedGoogle Scholar
• Audisio RA , RameshH, LongoWEet al. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist10(4), 262–268 (2005).
   PubMed Web of Science ®Google Scholar
• Resorlu B , BedukY, BaltaciSet al. The prognostic significante of advanced age in patient with bladder cancer treated with radical cystectomy. BJU Int.103(4), 480–483 (2008).
   PubMed Web of Science ®Google Scholar
• Bamias A , EfstathuousE, MoulopoulosLAet al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann. Oncol.16(2), 307–313 (2005).
   PubMed Web of Science ®Google Scholar